ECM Weekly (25 October 2020) - Ant Group, Lufax, JW Thera, Shimao Svcs, GDS Secondary, Nanofilm
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. This week...
884 Views
What HKEX Biotech "Step-Ups" Can Tell Us
This Insight explains the concept of valuation "step-ups" for pre-revenue biotechnology companies listing on the HKEX and how to use this data to...
582 Views
JW Therapeutics IPO: Valuation Insights
The core drug candidate’s competitive advantage in the China CAR-T market, a good cornerstone investor lineup and our valuation analysis suggest...
609 Views
JW Therapeutics (药明巨诺) IPO: Free Options for Potential License-In
We think at the high-end pricing, investors are getting a free option for their potential in-license products for JW Therapeutics.
527 Views
JW Therapeutics IPO Initiation: Potent Medicine
JW’s core drug candidate’s competitive advantage is supported by its potential best-in-class safety profile with competitive efficacy, physicians’...
495 Views